Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

Completed · Phase 4

Conditions studied: Diabetic Peripheral Neuropathy

In brief

The purpose of this study is to 1) provide continued pregabalin treatment for 6 additional months to patients who have taken part in the placebo controlled study A0081060; and 2) find out if pregabalin is safe at a dose of 600 mg/day (taken twice a day)

Key facts

Study ID

NCT00159731

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

160

Starts

2005-01-01

Expected to finish

2006-05-01

Last updated by the study team

2021-01-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults with Type 1 or 2 diabetes
• Patients must have pain in their lower legs or feet due to painful diabetic neuropathy that has lasted for at least 3 months

You may not qualify if…

• Patients must not be in poor or unstable health.

Where it is running

• Pfizer Investigational Site — Hot Springs, Arkansas, United States
• Pfizer Investigational Site — La Jolla, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Torrance, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Ocala, Florida, United States
• Pfizer Investigational Site — Ocala, Florida, United States
• Pfizer Investigational Site — Palm Beach Gardens, Florida, United States
• Pfizer Investigational Site — Sunrise, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Omaha, Nebraska, United States
• Pfizer Investigational Site — Omaha, Nebraska, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — Englewood, New Jersey, United States
• Pfizer Investigational Site — New Brunswick, New Jersey, United States
• Pfizer Investigational Site — Albany, New York, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Greenville, North Carolina, United States
• Pfizer Investigational Site — Toledo, Ohio, United States
• Pfizer Investigational Site — Duncansville, Pennsylvania, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.